Asia Pacific

2018

16/05/2018 Guerbet announces the acquisition of a new microsphere technology to strengthen its interventional imaging range

• Acquisition of a technology developed by Occlugel, a French company specialized in the R&D of microspheres used in embolization; • This new technology will round out Guerbet’s Interventional Imaging solutions and create synergies with the Accurate range of anti-reflux...

[more]


16/05/2018 GEAR 2023 strategic plan

Villepinte, April 18, 2018 – Guerbet (the “Company”), a global specialist in contrast agents and solutions for medical imaging, has released today its GEAR 2023 strategic plan.

[more]


23/04/2018 1st quarter 2018 revenue

1st quarter 2018 revenue €196.5 million at constant exchange rates: -3.2% Villepinte, April 18, 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €183.2 million for the 1st quarter 2018, down 9.8% at...

[more]


16/01/2018 Guerbet announces its acquisition of Accurate Medical Therapeutics

Guerbet announces its acquisition of Accurate Medical Therapeutics, an innovative company that develops microcatheters for interventional radiology > Acceleration of the interventional radiology strategy > Acquisition of a unique technology for image-guided embolization...

[more]


16/01/2018 Gadolinium-based contrast agents: update from Guerbet LLC on U.S. FDA requirements

Gadolinium-based contrast agents: update from Guerbet LLC on U.S. Food and Drug Administration (FDA) requirements Princeton (USA)–Guerbet LLC takes note of the drug safety communication1 issued on December 19, 2017 by the U.S. Food and Drug Administration (FDA), regarding gadolinium-based...

[more]